[go: up one dir, main page]

WO2014036438A3 - Vaccins vivants contre la brucellose comprenant des mutants atténués de brucella - Google Patents

Vaccins vivants contre la brucellose comprenant des mutants atténués de brucella Download PDF

Info

Publication number
WO2014036438A3
WO2014036438A3 PCT/US2013/057578 US2013057578W WO2014036438A3 WO 2014036438 A3 WO2014036438 A3 WO 2014036438A3 US 2013057578 W US2013057578 W US 2013057578W WO 2014036438 A3 WO2014036438 A3 WO 2014036438A3
Authority
WO
WIPO (PCT)
Prior art keywords
brucella
vaccines
mutants
live
attenuated brucella
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/057578
Other languages
English (en)
Other versions
WO2014036438A2 (fr
Inventor
David W. Pascual
Xinghong YANG
Beata CLAPP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Montana State University Bozeman
Original Assignee
Montana State University Bozeman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Montana State University Bozeman filed Critical Montana State University Bozeman
Publication of WO2014036438A2 publication Critical patent/WO2014036438A2/fr
Publication of WO2014036438A3 publication Critical patent/WO2014036438A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Cette invention concerne des vaccins à base de Brucella qui protègent contre les infections à Brucella et la brucellose. Ces vaccins peuvent conférer une résistance croisée qui protège contre les infections provoquées par d'autres souches de Brucella. Des souches de Brucella qui peuvent être utilisées dans les vaccins, et des méthodes permettant d'induire une immunité contre l'infection à Brucella chez un mammifère et de différencier les mammifères immunisés des mammifères non immunisés sont en outre décrites.
PCT/US2013/057578 2012-08-30 2013-08-30 Vaccins vivants contre la brucellose comprenant des mutants atténués de brucella Ceased WO2014036438A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261695205P 2012-08-30 2012-08-30
US61/695,205 2012-08-30
US201361783367P 2013-03-14 2013-03-14
US61/783,367 2013-03-14

Publications (2)

Publication Number Publication Date
WO2014036438A2 WO2014036438A2 (fr) 2014-03-06
WO2014036438A3 true WO2014036438A3 (fr) 2014-04-24

Family

ID=50184661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/057578 Ceased WO2014036438A2 (fr) 2012-08-30 2013-08-30 Vaccins vivants contre la brucellose comprenant des mutants atténués de brucella

Country Status (1)

Country Link
WO (1) WO2014036438A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103952428B (zh) * 2014-04-11 2016-08-17 中国人民解放军军事医学科学院军事兽医研究所 布鲁氏菌菌壳疫苗株的制备方法
CN113025640B (zh) * 2021-03-17 2023-09-12 天康生物制药有限公司 一种布鲁氏菌外膜囊泡的制备方法及其应用
CN114075551B (zh) * 2021-06-11 2024-01-26 华中农业大学 沙林鼠种布鲁氏菌脂多糖的单克隆抗体及应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241188A1 (en) * 2003-02-28 2004-12-02 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services Recombinant human metapneumovirus and its use
US20110033492A1 (en) * 2007-12-19 2011-02-10 Dominic Charles Jenner Vaccines for brucellosis
US20120202270A1 (en) * 2008-10-30 2012-08-09 Schurig Gerhardt G Producing an immune response for reducing the risk of developing brucellosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241188A1 (en) * 2003-02-28 2004-12-02 The Government Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Services Recombinant human metapneumovirus and its use
US20110033492A1 (en) * 2007-12-19 2011-02-10 Dominic Charles Jenner Vaccines for brucellosis
US20120202270A1 (en) * 2008-10-30 2012-08-09 Schurig Gerhardt G Producing an immune response for reducing the risk of developing brucellosis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PASCUAL, DW.: "Brucellosis Vaccine", 19 August 2011 (2011-08-19), Retrieved from the Internet <URL:http://portal.nifa.usda.gov/web/crisprojectpages/0219665-brucellosis-vaccine-mt.html> [retrieved on 20140212] *

Also Published As

Publication number Publication date
WO2014036438A2 (fr) 2014-03-06

Similar Documents

Publication Publication Date Title
WO2013054199A3 (fr) Antigènes de cmv et leurs utilisations
ZA201500784B (en) Mycobacterial antigen vaccine
EP3067866A4 (fr) Procédé et dispositif destinés à convertir une vue virtuelle en une vue stéréoscopique
EP3200831A4 (fr) Vaccins possédant un antigène et une interleukine-21 en tant qu&#39;adjuvant
IL244642B (en) A twisted-graphene wideband optical limiter for the protection of back-illuminated cmos detectors
PH12014502855A1 (en) Attenuated streptococcus suis vaccines and methods of making and use thereof
HK1219045A1 (zh) 增强对肠道病原体免疫应答的组合物和方法
PH12015501101B1 (en) Method for eliciting an immune response to an immunogen
HUE047484T2 (hu) Készítmények és eljárások eimeria elleni immunválasz fokozására vagy eimeria-fertõzés korlátozására
WO2013084071A3 (fr) Vaccin à base de toxines de clostridium difficile
MX2017016401A (es) Composiciones inmunogenas.
EP3024482A4 (fr) Procédés permettant de diagnostiquer et de traiter une maladie du système immunitaire
EP3113859A4 (fr) Oxyde de cérium (iv) ayant d&#39;exceptionnelles propriétés d&#39;élimination de l&#39;arsenic
WO2012170097A3 (fr) Compositions et procédés pour l&#39;induction de réponses immunitaires contre des bactéries du genre staphylococcus
WO2014036438A3 (fr) Vaccins vivants contre la brucellose comprenant des mutants atténués de brucella
HK1254514A1 (zh) 用於增强疫苗接种免疫反应的方法及组合物
WO2011100408A3 (fr) Corrélats sérologique de protection contre une infection par bacillus anthracis
EP3538197A4 (fr) Dispositifs et procédés d&#39;amélioration de l&#39;immunogénicité vis-à-vis d&#39;une vaccination intradermique
MX2019008779A (es) Antigenos de pseudomonas y combinaciones de antigenos.
WO2014165164A3 (fr) Compositions et procédés destinés au traitement de maladies auto-immunes
HK1224187A1 (zh) 针对药物成瘾的疫苗组合物
WO2014166501A3 (fr) Utilisation de peptides immunosuppresseurs en tant qu&#39;adjuvants
ES2586979A1 (es) Vacunas vivas atenuadas de staphylococcus aureus
IL234629B (en) An immunogenic preparation for use in a method for increasing a protective immune response against Haemophilus influenzae infection and a process for its preparation
GB201120634D0 (en) Adjuvant polypeptide

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13832803

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13832803

Country of ref document: EP

Kind code of ref document: A2